IFN-α as a vaccine adjuvant: Recent insights into the mechanisms and perspectives for its clinical use

Expert Review of Vaccines

Volumn 10, Issue 4, 2011, Pages 487-498

  Rizza, Paola ^a   Capone, Imerio ^a   Moretti, Franca ^a   Proietti, Enrico ^a   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

adjuvant; cancer; dendritic cell; immunity; infectious diseases; interferon; vaccine

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; CANCER VACCINE; HEPATITIS B VACCINE; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERFERON; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RESIQUIMOD;

CLINICAL TRIAL (TOPIC); DENDRITIC CELL; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; COMMUNICABLE DISEASE CONTROL; HUMANS; INTERFERON-ALPHA; NEOPLASMS; VACCINES;

EID: 79955081753     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.9     Document Type: Review

References (86)

1. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity 25(3), 343-348 (2006). (Pubitemid 44354219)
2. Belardelli F, Gresser I. The neglected role of type I interferon in the T cell response: implications for its clinical use. Immunol. Today 17(8), 369-372 (1996). (Pubitemid 26247796)
3. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23(4), 201-208 (2002). (Pubitemid 34260936)
4. Santini SM, Lapenta C, Logozzi M et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191(10), 1777-1788 (2000). (Pubitemid 30331574)
5. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43(3), 204-209 (2010).
6. Tovey MG, Lallemand C, Thyphronitis G. Adjuvant activity of type I interferons. Biol. Chem. 389(5), 541-545 (2008). (Pubitemid 351874185)
7. Bracci L, La Sorsa V, Belardelli F, Proietti E. Type I interferons as vaccine adjuvants against infectious diseases and cancer. Expert Rev. Vaccines 7(3), 373-381 (2008). (Pubitemid 351520025)
8. Toporovski R, Morrow MP, Weiner DB. Interferons as potential adjuvants in prophylactic vaccines. Expert. Opin. Biol. Ther. 10(10), 1489-1500 (2010).
9. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 237(5963), 291-295 (2010).
10. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272(5270), 1947-1950 (1996). (Pubitemid 26234507)
11. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188(12), 2335-2342 (1998). (Pubitemid 29028505)
12. Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4(10), 1009-1015 (2003). (Pubitemid 37265922)
13. Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type I interferon-producing cells in human blood. Science 284(5421), 1835-1837 (1999).
14. Cella M, Jarrossay D, Facchetti F et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5(8), 919-923 (1999). (Pubitemid 29372419)
15. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann. NY Acad. Sci. 1183, 89-103 (2010).
16. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 19(1), 3-19 (2008).
17. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8(8), 594-606 (2008).
18. Le Bon A, Schiavoni G, D'antigenostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14(4), 461-470 (2001). (Pubitemid 32441598)
19. Paquette RL, Hsu NC, Kiertscher SM et al. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64(3), 358-367 (1998). (Pubitemid 28409243)
20. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294(5546), 1540-1543 (2001). (Pubitemid 33063928)
21. Parlato S, Santini SM, Lapenta C et al. Expression of CCR-7, MIP-3β, and Th-1 chemokines in type I IFN-induced monocyte- derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98(10), 3022-3029 (2001).
22. Santodonato L, D'antigenostino G, Nisini R et al. Monocyte-derived dendritic cells generated after a short-term culture with IFN-α and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response. J. Immunol. 170(10), 5195-5202 (2003). (Pubitemid 36554752)
23. Lapenta C, Santini SM, Logozzi M et al. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated-virus-pulsed dendritic cells generated in the presence of IFN-α. J. Exp. Med. 198(2), 361-367 (2003). (Pubitemid 36987861)
24. Tosi D, Valenti R, Cova A et al. Role of cross-talk between IFN-α-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J. Immunol. 172(9), 5363-5370 (2004). (Pubitemid 38542035)
25. Lapenta C, Santini SM, Spada M et al. IFN-α-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T-cells against exogenous viral antigens even in the absence of CD4+ T-cell help. Eur. J. Immunol. 36(8), 2046-2060 (2006). (Pubitemid 44251751)
26. Gabriele L, Borghi P, Rozera C et al. IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 103(3), 980-987 (2004). (Pubitemid 38129560)
27. Salem ML, El-Naggar SA, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the Toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24(24), 5119-5132 (2006). (Pubitemid 43818196)
28. Stahl-Hennig C, Eisenblätter M, Jasny E et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 5(4), e1000373 (2009).
29. Trumpfheller C, Caskey M, Nchinda G et al. The microbial mimic poly I:C induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl Acad. Sci. USA 105(7), 2574-2579 (2008). (Pubitemid 351520555)
30. + Th1 immunity with poly I:C as adjuvant. J. Exp. Med. 206(7), 1589-1602 (2009).
31. + (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207(6), 1247-1260 (2010).
32. + dendritic cells. J. Exp. Med. 207(6), 1273-1281 (2010).
33. + dendritic cells. J. Exp. Med. 207(6), 1261-1271 (2010).
34. + dendritic cells. J. Exp. Med. 207(6), 1283-1292 (2010).
35. + dendritic cell subset. Immunol. Rev. 234(1), 18-31 (2010).
36. Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 27(3), 370-383 (2007). (Pubitemid 47418682)
37. Gaspari AA, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J. Drugs Dermatol. 8(5), 467-474 (2009).
38. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, Diebold SS. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115(10), 1949-1957 (2010).
39. Dondi E, Rogge L, Lutfalla G, Uze G, Pellegrini S. Down-modulation of responses to type I IFN upon T cell activation. J. Immunol. 170(2), 749-756 (2003). (Pubitemid 36070525)
40. Chi B, Dickensheets HL, Spann KM et al. a and l interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J. Virol. 80(10), 5032-5040 (2006).
41. Le Bon A, Thompson C, Kamphuis E et al. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 176(4), 2074-2078 (2006). (Pubitemid 43201653)
42. Havenar-Daughton C, Kolumam GA, Murali-Krishna K. Cutting edge: the direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection. J. Immunol. 176(6), 3315-3319 (2006). (Pubitemid 43363977)
43. Krug A, Veeraswamy R, Pekosz A et al. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells. J. Exp. Med. 197(7), 899-906 (2003). (Pubitemid 36437866)
44. + T cells altering their response to antigen. J. Immunol. 183(5), 2915-2920 (2009).
45. Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr. Opin. Hematol. 16(4), 274-279 (2009).
46. Pace L, Vitale S, Dettori B et al. APC activation by IFN-α decreases regulatory T cell and enhances Th cell functions. J. Immunol. 184(11), 5969-5979 (2010).
47. Ascierto PA, Napolitano M, Celentano E et al. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment. J. Transl. Med. 8, 76 (2010).
48. Querec TD, Akondy RS, Lee EK et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10(1), 116-125 (2009).
49. Gaucher D, Therrien R, Kettaf N et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205(13), 3119-3131 (2008).
50. + T cell response during cross-priming. J. Immunol. 176(8), 4682-4689 (2006).
51. Proietti E, Bracci L, Puzelli S et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J. Immunol. 169(1), 375-383 (2002). (Pubitemid 34686158)
52. Tovey MG, Lallemand C, Meritet JF, Maury C. Adjuvant activity of interferon a: mechanism(s) of action. Vaccine 24(Suppl. 2), S2-46-47 (2006).
53. Bracci L, Canini I, Puzelli S et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23(23), 2994-3004 (2005). (Pubitemid 40462438)
54. Cull VS, Broomfield S, Bartlett EJ, Brekalo NL, James CM. Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice. Gene Ther. 9(20), 1369-1378 (2002). (Pubitemid 35244162)
55. Grob PJ, Joller-Jemelka HI, Binswanger U, Zaruba K, Descoeudres C, Fernex M. Interferon as an adjuvant for hepatitis B vaccination in non- and low-responder populations. Eur. J. Clin. Microbiol. 3(3), 195-198 (1984). (Pubitemid 14064343)
56. Strchler D, Berger R, Etlinger H et al. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. Vaccine 7(5), 457-461 (1989). (Pubitemid 19252631)
57. Goldwater PN. Randomized comparative trial of interferon-α versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine 12(5), 410-414 (1994). (Pubitemid 24107577)
58. Rizza P, Capone I, Urbani F et al. Evaluation of the effects of human leukocyte IFN-α on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine 26(8), 1038-1049 (2008).
59. Mennechet FJ, Uzè G. Interferon-l-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 107(11), 4417-4423 (2006). (Pubitemid 43801368)
60. Morrow MP, Pankhong P, Laddy DJ et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 113(23), 5868-5877 (2009).
61. Miquilena-Colina ME, Lozano- Rodríguez T, García-Pozo L et al. Recombinant interferon-a2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. Vaccine 27(41), 5654-5660 (2009).
62. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin. Dial. 20(5), 440-451 (2007).
63. Sester U, Sester M, Hauk M, Kaul H, Köhler H, Girndt M. T-cell activation follows Th1 rather than Th2 in haemodialysis patients. Neprhol. Dial. Transplant. 15(8), 1217-1223 (2000). (Pubitemid 30487801)
64. Launay O, Grabar S, Bloch F et al. Effect of sublingual administration of interferon-α on the immune response to influenza vaccination in institutionalized elderly individuals. Vaccine 26(32), 4073-4079 (2008).
65. Couch RB, Atmar RL, Cate TR et al. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine 27(39), 5344-5348 (2009).
66. Bracarda S, Eggermont AM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer. 46(2), 284-297 (2010).
67. Ferrantini M, Belardelli F. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer. Biol. 10(2), 145-157 (2000). (Pubitemid 30458474)
68. Ferrantini M, Capone I, Belardelli F. Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89(6-7), 884-893 (2007). (Pubitemid 47001642)
69. + T cell numbers, effector function, and antitumor activity. J. Immunol. 182(12), 7398-7407 (2009).
70. Hance KW, Rogers CJ, Zaharoff DA, Canter D, Schlom J, Greiner JW. The antitumor and immunoadjuvant effects of IFN-α in combination with recombinant poxvirus vaccines. Clin. Cancer Res. 15(7), 2387-2396 (2009).
71. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354(7), 709-718 (2006). (Pubitemid 43247141)
72. Crow MK. Type I interferon in systemic lupus erythematosus. Curr. Top. Microbiol. Immunol. 316, 359-386 (2007).
73. Banchereau J, Pascual V. Type I IFN in systemic lupus erythematosus and other autoimmune diseases. Immunity 25(3), 383-392 (2006). (Pubitemid 44354221)
74. Koon H, Atkins M. Autoimmunity and immunotherapy of cancer. N. Engl. J. Med. 354(7), 758-760 (2006).
75. + T cells and monocyte/dendritic cell precursors. Cancer Res. 66(9), 4943-4951 (2006).
76. Kirkwood JM, Lee S, Moschos SJ et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/- granulocyte-monocyte colony-stimulating factor and/or IFN-a2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res. 15(4), 1443-1451 (2009).
77. + blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 81(3), 584-592 (2007). (Pubitemid 46393535)
78. Krutzik SR, Tan B, Li H et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 11(6), 653-660 (2005). (Pubitemid 40868306)
79. Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B. Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-α during treatment of melanoma. Immunobiology 215(2), 113-123 (2010).
80. Nisticò P, Capone I, Palermo B et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer. 124(1), 130-139 (2009).
81. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449(7161), 419-426 (2007). (Pubitemid 47509552)
82. Parlato S, Romagnoli G, Spadaro F et al. LOX-1 as a natural IFN-α-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 115(8), 1554-1563 (2010).
83. Rouzaut A, Garasa S, Teijeira A et al. Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α. Eur. J. Immunol. 40(11) 3054-3063 (2010).
84. Vermi W, Fisogni S, Salogni L et al. Spontaneous regression of highly immunogenic molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J. Invest. Dermatol. 131(2) 426-434 (2010).
85. Moschella F, Proietti E, Capone I, Belardelli F. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann. NY Acad. Sci. 1194, 169-178 (2010).
86. Locher C, Conforti R, Aymeric L et al. Desirable cell death during anticancer chemotherapy. Ann. NY Acad. Sci. 1209, 99-108 (2010).